Attach to Form 990 or Form 990-EZ.
Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.
| (i)Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Total | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | 36,423,872 | 34,135,315 | 55,590,601 | 40,345,846 | 33,315,225 | 199,810,859 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 36,423,872 | 34,135,315 | 55,590,601 | 40,345,846 | 33,315,225 | 199,810,859 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 8,010,574 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 191,800,285 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 36,423,872 | 34,135,315 | 55,590,601 | 40,345,846 | 33,315,225 | 199,810,859 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 193 | 1,753 | 3,388 | 4,222 | 3,819 | 13,375 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support Add lines 7 through 10. | 199,824,234 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e | Discount claimed for blockage or other factors (explain in detail in Part VI): | |||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| 7 | Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions) | |||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2014 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2014 |
(iii) Distributable Amount for 2014 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2014 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2014 (reasonable cause required--see instructions) |
||||
| 3 Excess distributions carryover, if any, to 2014: | ||||
| a From 2009.......X | ||||
| b From 2010.......X | ||||
| c From 2011.......X | ||||
| d From 2012.......X | ||||
| e From 2013....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2014 distributable amount | ||||
|
i
Carryover from 2009 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2014 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2014 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2014, if any. Subtract lines 3g and 4a from line 2 (if amount greater than zero, see instructions) |
||||
|
6
Remaining underdistributions for 2014. Subtract lines 3h and 4b from line 1 (if amount greater than zero, see instructions) |
||||
|
7 Excess distributions carryover to 2015. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a From 2010.......X | ||||
| b From 2011.......X | ||||
| c From 2012.......X | ||||
| d From 2013....... | ||||
| e From 2014....... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | 14000292 |
| Software Version: | 14.4.1.0 |
Attach to Form 990 or 990-EZ.
Information about Schedule O (Form 990 or 990-EZ) and its instructions is at| Return Reference | Explanation |
|---|---|
| Form 990, Part I, Line 1 | The American Diabetes Association Research Foundation, Inc. the Foundation secures major gifts and grants to fund diabetes-related research. |
| Form 990, Part III, Line 4 | Changing Lives through Research The vast majority of diabetes cases, both type 1 and type 2, are polygenic diseases, meaning that more than one gene contributes to risk of and progression to diabetes. However, some very rare forms of diabetes are caused by single gene mutations and are called monogenic diabetes. Monogenic diabetes appears in newborns up to about six to nine months of age. As neonatal monogenic diabetes is rare, these individuals are often misdiagnosed as having type 1 diabetes and are treated with insulin. However, because the single gene mutations that cause the disease dont necessarily result in total insulina hormone that helps the body use glucose for energy. The beta cells of the pancreas make insulin. When the body cannot make enough insulin, it is taken by injection or through use of an insulin pump deficiencies like type 1 diabetes a condition characterized by high blood glucose levels caused by a total lack of insulin. Occurs when the bodys immune system attacks the insulin-producing beta cells in the pancreas and destroys them. The pancreas then produces little or no insulin. Type 1 diabetes develops most often in young people but can appear in adults, oral diabetes medications like sulfonylureas can sometimes be used to better manage monogenic diabetes. The correct diagnosisthe determination of a disease from its signs and symptoms. of monogenic diabetes is critical and can make a significant impact in the lives of the patients. However, the study of rare diseases can be especially difficult, in part because of the challenge in identifying sufficient numbers of patients to study. With funding from the American Diabetes Association, Dr. Louis Philipson created the first registry for individuals with monogenic diabetes. Using web-based technologies, the University of Chicago Monogenic Diabetes Registry allows for the successful recruitment of a relatively large number of patients with monogenic diabetes who are providing great insight into our understanding of these sub-types of diabetes, and how best to treat them. Data can be efficiently collected and maintained in a secure and confidential manner. Now DNA from people diagnosed with diabetes in the first several months of life can be tested for known mutations. If a defined mutation is confirmed, these patients may be able to transition from insulin therapy to sulfonylureaa class of oral medicine for type 2 diabetes that lowers blood glucose by helping the pancreas make more insulin and by helping the body better use the insulin it makes Generic names acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide an oral medication, to effectively manage their diabetes. The more we learn about links between genetics and diabetes through biomedical research, the better able we are to develop and deploy the correct treatment regimen to treat individuals based on their specific genetic make-up. Because of the work of individuals like Dr. Philipson, we now know that individuals who have been diagnosed with diabetes as infants are more likely to have monogenic diabetes, and that they should be tested at a center that specializes in monogenic diabetes. The documentary Journey to a Miracle Freedom From Insulin, which was released in January 2015, tells the story of several parents who discovered their children had monogenic diabetes, a rare form of diabetes caused by genetic mutations. The diagnosis allowed the kids to swap insulin for oral medications, radically changing their lives. The film also tells the story of the science, highlighting the researchers and doctors who played an integral role in breakthrough studies on and treatment of monogenic diabetes. It documents the beginning of what many hope is a greater awareness of the rare disease. |
| Form 990, Part III, Line 4 Continued | The American Diabetes Associations direct involvement in diabetes research extends back to the 1940s when Dr. Charles H. Best, one of four scientists credited with discovering insulin, provided the Association with the framework and early leadership for a formalized diabetes research program. Since our Research Programs inception in 1952, we have been the leader in funding cutting-edge diabetes research, supporting nearly 4,500 research projects and investing more than 700 million in diabetes research. In 2014, the Association made nearly 30 million available to support 376 new and continuing research projects performed by 364 investigators at 143 leading research institutions. The primary goals of the Associations Research Program are -Support the highest quality science across the broad spectrum of diabetes research. -Support investigators early in their careers to encourage them to dedicate their efforts to diabetes research. - Support investigators early in their careers to encourage them to dedicate their efforts to diabetes research. |
| Form 990, Part III, Line 4 Continued | Peer Review Process One of the factors that sets American Diabetes Association-funded research apart and ensures that we are supporting the very best science is peer review. Peer review is a process whereby grant applications are reviewed and evaluated by individuals who are experts in the field or peers of the individual submitting the grant. Association grant applications all undergo peer review by three or more volunteer experts who are themselves diabetes researchers. Reviewers provide both a score and detailed comments regarding the strengths and weaknesses of each grant they review. Scores from all reviewers for each grant are averaged to arrive at a composite merit score that is then used to determine which grants to support. Types of Research Awards Research awards are divided into four major categories that reflect our research goals and priorities, provide extraordinary opportunities for researchers from diverse backgrounds, and foster the professional development of young scientists interested in diabetes research. The categories are Investigator-Initiated Awards Core Program Pathway to Stop Diabetes Collaborative Targeted Research and Research Co-Support. Approximately 80 of Association-funded research falls under the Core Research Awards. In 2014, the Research Policy Committee undertook a critical and comprehensive strategic review of the core research program grant offerings and restructured the portfolio to improve efficiencies and better align with organizational objectives. The new programmatic offerings were launched for the 2015 Core Research Program annual call for applications. |
| Form 990, Part III, Line 4 Continued | Research Program Outcomes American Diabetes Association-funded researchers show an exemplary commitment to advancing their careers within the field of diabetes research. Within five years of their award 98 remain in diabetes research Average 6 publications per award 85 of career development awardees receive promotions 85 receive subsequent federal funding to support their work, resulting in a 7.5 fold increase in funding from other sources Pathway to Stop Diabetes We understand the importance of shaping the track and making it accessible to new top talent. In 2014, to accelerate the research needed to discover solutions and ultimately cure diabetes, the American Diabetes Association launched a bold initiative, Pathway to Stop Diabetes, to inspire a new generation of diabetes researchers. With a goal of funding 100 new diabetes researchers over the next decade, Pathway provides crucial support to individuals focusing on innovative ideas and transformational approaches that will lead to new discoveries in diabetes prevention and treatment. Importantly, Pathway is in addition to ongoing Association research activities, and will significantly expand our research efforts. Pathway supports creative scientists who are early in their career, or who are established but would like to expand their focus on diabetes research regardless of their current field of study. Through awards of 1.625 million over the course of five to seven years, the program will allow researchers to have the time and focus needed to explore new ideas. |
| Form 990, Part III, Line 4 Continued | The first class of five Pathway Scientists began their awards in January 2014. Collectively the awardees published three high-impact publications, gave 10 presentations at scientific meetings, presented 24 invited lectures and filed one patent application, all resulting from Pathway funding in the first year. In addition, the inaugural Pathway to Stop Diabetes Symposium debuted at the 74th Scientific Sessions in San Francisco, bringing together the Mentor Advisory Group, program sponsors and Association leadership to witness firsthand the exciting projects and impressive progress of the first class of Pathway Scientists. The Association also held the second annual Pathway to Stop Diabetes grant competition. The Mentor Advisory Group reviewed 116 outstanding nominations and selected six new Pathway Awardees who were announced and started their grants in January 2015. 2014 Research Highlights The Association sponsored a new collaborative targeted funding opportunity Chronic Kidney Disease in the Setting of Diabetes with Boehringer Ingelheim, supporting research in this high-need area defined by an Association consensus conference. Association-supported researchers made significant progress in understanding how diabetes develops and progresses, and in identifying new ways to potentially combat the disease. Notable advances include studies uncovering surprising connections between the gut microbiome and metabolism, development and testing of new devices that integrate glycemic control with hypoglycemia prevention for artificial pancreas technologies, and studies uncovering the conditions and mechanisms from the maternal environment that confer risk for diabetes and obesity to the offspring. |
| Form 990, Part III, Line 4 Continued | Headlines from projects supported by the American Diabetes Association Research Program in 2014 - Mothers Diet Affects Brain Development and Metabolism in Offspring - The Obesity Paradox - Does Excess Weight Improve Survival - Uncovering a New Key to Increased Heart Disease Risk in Diabetes - Type 2 Diabetes Gene Acts through Neighboring Pancreas Cells - Diet During Pregnancy Affects Offspring Later in Life - Progress in Artificial Pancreas Development Preventing and Treating Low Blood Glucose - Reducing Cardiovascular Disease Risk in Youth with Type 1 Diabetes - A Genetic Link to Type 2 Diabetes in Obesity - A Close-Up View of Glucose Transport - Regenerating Human Beta Cells - Addressing Obstacles to Islet Transplantation - Improving Technology to Save Eyesight Scientific Sessions Held annually, Scientific Sessions exemplifies the American Diabetes Associations leadership role in the global diabetes community, while providing a critical platform for driving diabetes awareness. Scientific Sessions is the worlds largest scientific and medical meeting focused on the latest basic and clinical science research related to diabetes and its complications. The 73rd Annual Scientific Sessions, held in Chicago, June 21-25, 2013, brought together more than 17,600 scientists, health care professionals and industry representatives from 117 countries. The program included more than 700 speakers, delivering presentations in symposia, major lectures and oral abstract sessions, and 2,178 original research poster presentations. In addition, more than 155 companies showcased their latest products and services in the Exhibit Hall. |
| Form 990, Part VI, Section A, Line 1a | The main responsibilities and focus of the Foundations Board is to advance, support, and promote charitable contributions by soliciting major gifts for the purpose of funding the American Diabetes Associations Nationwide Research Program. The Board of Directors of the Foundation provides governance over the activities of the Foundation in accordance with the purposes, policies, and procedures of the American Diabetes Association. The Board delegates to the Foundations Executive Committee responsibility for management of the Foundation when the Board is not in session. The American Diabetes Association provides complete operational support to the Foundation including staff, facilities and administrative processes. The Foundations annual budget and audit process are governed by the American Diabetes Association Board of Directors and Audit Committee. |
| Form 990, Part VI, Section A, Line 3,7a,7b | The Foundations affairs are managed by the Foundation Board of Directors. The Board of Directors of the Foundations supervises, directs, and controls the activities of the Foundation in accordance with the mission, purposes, policies and procedures of the American Diabetes Association. The Board delegates to the Foundations Executive Committee responsibility for management of the Foundation when the Board is not in session. The American Diabetes Association provides complete operational support to the Foundation including staff, facilities and administrative processes. The Foundations annual budget and audit process are governed by the American Diabetes Association Board of Directors and Audit Committee. If a vacancy occurs among the Foundations officers for any reason, the Board of Directors of the American Diabetes Association shall fill such position for the unexpired portion of the term. |
| Form 990, Part VI, Section B, Line 11a | IRS Form 990 Review Process by the Governing Body The American Diabetes Association Research Foundation the Foundation draft IRS 990 is reviewed by the American Diabetes Associations management and KPMG. The final and signed IRS Form 990 was provided to the Associations Board of Directors prior to filing with the IRS. . The form was made available to the Foundations Board of Directors after filing with the IRS. |
| Form 990, Part VI, Section B, Line 12c | Managing a Conflict of Interest To identify potential conflicts of interest with appropriate due diligence, the Foundations Officers, Directors, and members of the Grant Review Panel must annually disclose any potential conflicts of interest. The American Diabetes Associations Audit Committee and senior staff in legal affairs manage the disclosure and monitoring processes of the Board. The senior staff on the Associations Scientific and Medical Division manage the disclosure and monitoring processes of the Grant Review Panel. Through review of the annual disclosures and review of the agendas of relevant Board, Committee and other meetings, appropriate efforts are made in advance of the meetings to identify potential conflicts of interest. Each person also has the responsibility to report his/her own conflicts of interest actual or perceived as those conflicts may arise during a meeting. |
| Form 990, Part VI, Section B, Line 12c | Research Grants Review Committee Conflict of Interest COI within the Research Grants Review Committee is managed through a written COI policy and through COI declarations signed both before and after the review cycle. The COI for grant reviewers is self-reported. The primary considerations addressed in the COI policy and program guidelines are as follows - Institutional Individuals are required to recuse themselves from reviewing grants for scientists at the same institution, including any institutions with which they may be negotiating employment. - Financial Individuals are required to recuse themselves from reviewing grants from which they stand to gain financially if the grant is awarded co-PI, collaborator, subcontracts, etc.. Personal Individuals are required to recuse themselves from reviewing grants for investigators with whom they either have a personal or professional relationship collaborators, colleagues or personal friends, or a long standing professional or scientific disagreement that prevents them from unbiased review. |
| Form 990, Part VI, Section B, Line 13 | The American Diabetes Association has a written Document Retention and Destruction policy that applies to the American Diabetes Association Research Foundation. |
| Form 990, Part VI, Section C, Line 14 | The American Diabetes Association has a written Document Retention and Destruction policy that applies to the American Diabetes Association Research Foundation. |
| Form 990, Part VI, Section C, Line 17 | Filing Jurisdiction - Registration Filing Jurisdiction - Registration Alabama AL97-256 Minnesota N/A Alaska N/A Mississippi 100000294 Arkansas N/A New Hampshire 5006 California CT81471 New Jersey CH-0581900 Colorado 2002-3003670 New Mexico N/A Connecticut 5084 New York 01/30/65 District of Columbia 981855 North Carolina SL000618 Florida CH1618 North Dakota 7894 Georgia CH-001422 Ohio 01-0239 Hawaii N/A Oklahoma N/A Illinois CO 01-025537 Oregon 1640 Indiana 000103829-000 Pennsylvania No. 21 Kansas 177-257-3SO Rhode Island 95-23 Kentucky 45 South Carolina 641 Louisiana N/A Tennessee 5104 Maine CO-1247 Utah 6536093-Cha Maryland 102 Virginia N/A Massachusetts O29317 Washington 7664 Michigan MICS 10326 West Virginia N/A Wisconsin 3020-800. |
| Form 990, Part VI, Section C, Line 19 | Document Disclosure The following documents are available on the American Diabetes Association website http//www.diabetes.org Board of Directors, audited Foundation financial statements, IRS Forms 990, and the whistleblower policy. Available subject to request to the American Diabetes Association Legal Affairs department are the following current bylaws, Articles of Incorporation, and the conflict of interest policy. |
| Form 990, Part VII, Section A, Line 4,7,18 | The Chief Executive Officer is a non-voting member of the Research Foundation Board of Directors. The Chief Executive Officer, the Chief Financial Officer, and the Chief Scientific Medical Officer are compensated by the American Diabetes Association based on a standard average of 38 hours per week. |
| Form 990, Part VII, Section A, Line 4 and 5 | Larry Hausner, Chief Executive Officers term ended July 31, 2014. M. Suzanne C. Berry, Berry 2 Associates began as Interim Chief Executive Officer as of August 1, 2014. |
| Form 990, Part XI, Line 9 | Other changes in net assets or fund balances of 646,705 reflect prior year research grant award refunds and forfeitures. |
| Software ID: | 14000292 |
| Software Version: | 14.4.1.0 |